Phase 2 N=234 DU-176b Phase 2 Dose Finding Study in Subjects With Non-valvular Atrial Fibrillation
Atrial Fibrillation · Stroke
Primary: Incidence of All Bleeding — 20.3; 23.8; 29.3 percentage of subjects with bleeds
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=23 Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive aHUS
Atypical Hemolytic Uremic Syndrome
Primary: Percentage of Patients With TMA Event-free Status — 80 Percentage of Participants
Phase 2 N=32 Efficacy of Potassium Nitrate Solution in Reducing Dentinal Hypersensitivity
Dentine Hypersensitivity
Primary: Between Treatment Comparison of the Adjusted Mean Change From Baseline of Response to Evaporative (Air) Stimuli Immediately Following Treatment on Day 5 Using a Visual…
Phase 2 N=60 Complement Inhibition With Eculizumab for the Treatment of Non-Exudative Macular Degeneration (AMD)
Age-Related Macular Degeneration
Primary: Growth of Geographic Atrophy — 0.18; 0.19 millimeters
Phase 2 N=55 Treatment of Adult Ph+ LAL With BMS-354825
Lymphoblastic Leukemia, Acute
Primary: Rate of Hematological Complete Remission (HCR) Obtained During the BMS Induction Treatment Within Day +85 From the Start of BMS (i.e., Whenever Achieved From the Start…
Phase 2 N=130 Memantine Hydrochloride in Helping Cancer Survivors Stop Smoking
Breast Cancer · Colorectal Cancer · Lung Cancer
Primary: Retention — 53.8; 67.7 percentage of participants
Phase 2 N=234 RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder
Acute Schizophrenia · Schizoaffective Disorder
Primary: Measurement of Schizophrenia Symptoms: Positive and Negative Syndrome Scale (PANSS) Total Score — 87.57; 88.74; 85.88; 91.68 scores on a scale
Phase 2 N=37 Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected Subjects
Chronic Hepatitis C · Hepatitis C Virus (HCV) Infection
Primary: Percentage of Participants With 4-week Rapid Virologic Response (RVR) — 33.3; 55.6; 70.0; 22.2 percentage of participants — p=0.336
Phase 2 N=100 Safety and Efficacy of Sufentanil NanoTab for Management of Acute Pain Following Bunionectomy
Acute Pain
Primary: SPID-12 — -5.65; 6.53; -7.12 units on a scale — p=0.742
Phase 2 N=112 A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension
Glaucoma · Ocular Hypertension
Primary: Change From Baseline in Average Eye Mean Diurnal Intraocular Pressure (IOP) — 24.54; 24.38; 24.29; -6.79 Millimeters of Mercury (mmHg)
Phase 2 N=523 A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty
Venous Thromboembolism · Deep Vein Thrombosis · Total Knee Arthroplasty
Primary: Proportion of Subjects With Venous Thromboembolism Events. — 29.5; 26.1; 12.5; 9.1 percentage of participants — p=<0.001
Phase 2 N=57 Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer
Ovarian Neoplasm
Primary: Confirmed Objective Tumour Response (According to Response Evaluation Criteria In Solid Tumors (RECIST) — 3; 11; 3; 11 Participants
Phase 2 N=54 Study to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of BRCA-positive Advanced Breast Cancer
Breast Neoplasms
Primary: Confirmed Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Criteria — 25.0; 42.3 Percentage of participants
Phase 2 N=23 Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (aHUS)
Atypical Hemolytic Uremic Syndrome
Primary: Percentage of Patients With TMA Event-free Status — 80 Percentage of Participants
Phase 2 N=40 Pharmacokinetic Study of 4 mg Nicotine Lozenge.
Smoking Cessation
Primary: Area Under the Curve From Time 0 to t, AUC (0-t) — 89.14; 87.38; 86.60; 91.97 nanograms (ng)*hours (h)/milliliter (mL)